PFE
FY2026 Q1 · Calendar Q2 2026
Pfizer Inc.
Pfizer's Q1 2026 results show the post-COVID turnaround continuing to build momentum. Revenue of $14.5B and adjusted EPS of $0.75 both exceeded consensus, driven by 22% operational growth in the launched and acquired portfolio led by Padcev, Nurtec, Eliquis, and Vyndamax. Legal settlements extending Vyndamax exclusivity to mid-2029 and a Belgian court ruling on Comirnaty improve cash-flow visibility and support a high-single-digit CAGR starting 2029. Management reaffirmed full-year guidance and highlighted roughly 20 pivotal study starts, 8 key readouts, and 4 regulatory decisions planned for 2026. Despite the beat, the stock saw a modest negative abnormal return on report day and has drifted approximately 4.2% lower subsequently, suggesting the market remains cautious about LOE pressures through 2028 and the 2028 timeline for the first obesity approval.
EPS surprise+3.9%
Market move+0.6%
